Featured Posts

Wall Street Journal
A Thumb on the Scale for Wegovy
The Biden administration announced one more bit of executive overreach on its way out the door. On Nov. 26, the Centers for Medicare and Medicaid…

Study
Evaluating Telehealth
Executive Summary Why Did We Write This Report Telehealth—the use of remote audio and/or video technologies to provide health care services—has been promoted as…

News Release
Report: Telehealth flexibility deadline looms, but Congress needs better information to decide
Congress is poised to consider proposals that permanently or temporarily extend flexibilities for telehealth services enacted during the COVID-19 pandemic that are set to expire…
Search Posts
HeartLand Daily News
FDA Hid COVID Shot Side Effects—Congressional Report
Heartland Daily News cited CEI on COVID public health concerns Joel Zinberg, M.D., senior fellow at the Competitive Enterprise Institute and director of the Public…
Op-Eds
Often Wrong, Never in Doubt
Times have changed. Two years ago, tennis great Novak Djokovic could not play in the U.S. Open tournament. It was not because he had Covid-19…
News Release
New FTC study on drug costs fails to conduct empirical analysis of market conditions
The Federal Trade Commission (FTC) release a new study today claiming Pharmacy Benefit Managers (PBMs) are responsible for higher drug costs. FTC Commissioner Melissa Holyoak…
Blog
New FDA lab tests rule could bankrupt small labs
Yesterday the Food and Drug Administration (FDA) announced that on May 6 it will promulgate a rule under its authority to regulate medical devices.
National Review
Covid Vaccines: An Update on Balancing Risks and Benefits
A new large, multi-country study has confirmed what previous smaller studies found: Covid-19 vaccines have risks. In particular, the messenger RNA (mRNA) vaccines from Pfizer and…
Comment
Comments RE: Docket No. FDA–2023–N–2177 for “Medical Devices; Laboratory Developed Tests
I am an attorney with the Competitive Enterprise Institute. The Competitive Enterprise Institute is a non-profit research and advocacy organization that focuses on regulatory policy.